Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUDIR8)

• Drug Name: Fludrocortisone Drug Info
• Synonyms: fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF; Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone

Indication

Disease Entry	ICD 11	Status	REF
Addison disease	5A74.0	Approved	[1]
Cerebral salt-wasting syndrome	5C72	Approved	[2]
Congenital adrenal hyperplasia	5A71.01	Approved	[1]

• Therapeutic Class: Antiinflammatory Agents
• Cross-matching ID:
  PubChem CID: 31378
  ChEBI ID: CHEBI:50885
  CAS Number: CAS 127-31-1
  TTD Drug ID: DMUDIR8
  INTEDE Drug ID: DR0705
  ACDINA Drug ID: D00282

Molecule-Related Drug Atlas

Drug(s) Targeting Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[8]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[9]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[10]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[11]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[12]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[13]
ARN-509	DMT81LZ	Acute myeloid leukaemia	2A60	Approved	[14]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[15]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[16]
Fluoxymesterone	DMUHCF1	Breast cancer	2C60-2C65	Approved	[17]

Drug(s) Targeting Mineralocorticoid receptor (MR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[18]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[19]
Desoxycorticosterone Acetate	DMS0AFE	Discovery agent	N.A.	Approved	[19]
Desoxycorticosterone Pivalate	DMSA4B3	Addison disease	5A74.0	Approved	[20]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[21]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[19]
Finerenone	DMM4FJ3	Chronic kidney disease	GB61	Approved	[22]
ZK-91587	DMJ94L0	Cardiovascular disease	BA00-BE2Z	Phase 2	[23]
Nerenone	DMBJ3GL	Diabetic nephropathy	GB61.Z	Phase 2	[24]
LY-2623091	DMFGNB4	Chronic kidney disease	GB61	Phase 2	[25]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[26]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[27]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[28]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[30]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[31]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[32]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[33]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[27]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[34]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[35]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[36]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[6]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[37]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[40]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[6]

Drug(s) Affected By Interleukin-1 alpha (IL1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[41]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[6]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[42]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[43]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[44]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[46]

Drug(s) Affected By Interleukin-1 beta (IL1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[47]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[48]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[49]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[6]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[51]
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[53]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[54]

Drug(s) Affected By Antileukoproteinase (SLPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[6]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[36]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[6]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[6]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[46]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[6]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[6]

Drug(s) Affected By Prostate-specific antigen (KLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[55]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[56]
Selenium	DM25CGV	N. A.	N. A.	Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[58]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[59]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[60]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[61]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[62]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[63]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[64]

Drug(s) Affected By Hepatocyte growth factor receptor (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[65]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[66]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[6]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[68]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[67]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[69]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[70]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[71]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[72]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[73]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[48]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[74]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[6]

Drug(s) Affected By C-C motif chemokine 3 (CCL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[75]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[43]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[76]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[77]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[78]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[79]
Betamethasone	DMAHJEF	Acute adrenal insufficiency		Approved	[7]
Emetine	DMCT2YF	Hepatitis virus infection	1E50-1E51	Approved	[7]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[75]

Drug(s) Affected By C-C motif chemokine 4 (CCL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[45]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[76]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[79]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[81]
Betamethasone	DMAHJEF	Acute adrenal insufficiency		Approved	[7]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[82]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[83]
Emetine	DMCT2YF	Hepatitis virus infection	1E50-1E51	Approved	[7]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[84]

Drug(s) Affected By C-C motif chemokine 2 (CCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[75]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[55]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[85]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[42]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[86]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[87]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[88]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[43]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[89]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[90]

Drug(s) Affected By Bone morphogenetic protein 6 (BMP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[6]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[6]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[6]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[6]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[6]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[92]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[6]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[93]

Drug(s) Affected By Prostaglandin G/H synthase 2 (PTGS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[94]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[95]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[96]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[97]
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[98]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[99]
Ibandronate	DM0QZBN	Hypercalcaemia	5B91.0	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[55]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[101]

Drug(s) Affected By Tumor necrosis factor-inducible gene 6 protein (TNFAIP6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Selenium	DM25CGV	N. A.	N. A.	Approved	[52]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[103]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[78]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[6]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[6]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[6]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[6]

Drug(s) Affected By PTB-containing, cubilin and LRP1-interacting protein (PID1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[6]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[6]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[6]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[6]
Amikacin	DM5PDRB	Bacteremia	1A73	Approved	[6]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[6]
Promethazine	DM6I5GR	Hyperemesis gravidarum		Approved	[6]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[6]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[104]

Drug(s) Affected By Cystine/glutamate transporter (SLC7A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[105]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[6]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[106]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[6]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[67]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[107]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[108]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Inhibitor	[3]
Mineralocorticoid receptor (MR)	TT26PHO	MCR_HUMAN	Agonist	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[6]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Gene/Protein Processing	[6]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Gene/Protein Processing	[7]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Gene/Protein Processing	[7]
C-C motif chemokine 4 (CCL4)	OT6B8P25	CCL4_HUMAN	Gene/Protein Processing	[7]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Gene/Protein Processing	[6]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[6]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Gene/Protein Processing	[6]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[6]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[6]

References

• [1] Fludrocortisone FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2873).
• [3] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [4] Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
• [5] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [6] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [7] Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
• [8] Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
• [9] Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [11] Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
• [12] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [13] Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
• [14] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [15] CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
• [16] Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
• [17] An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
• [18] Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [20] Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
• [21] Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
• [25] Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24.
• [26] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [27] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [28] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [29] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [30] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [31] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [32] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [33] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [34] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [35] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [36] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [37] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [38] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [39] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [40] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [41] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [42] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [43] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [44] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [45] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [46] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [47] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [48] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [49] Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction. J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
• [50] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [51] (9)-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J Pharmacol Exp Ther. 2019 Oct;371(1):191-201. doi: 10.1124/jpet.119.260661. Epub 2019 Aug 5.
• [52] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [53] Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
• [54] Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression. Apoptosis. 2006 Apr;11(4):573-9. doi: 10.1007/s10495-006-4919-3.
• [55] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [56] Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
• [57] Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
• [58] Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
• [59] EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
• [60] Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007 Aug 1;67(11):1152-62. doi: 10.1002/pros.20585.
• [61] Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
• [62] An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
• [63] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [64] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [65] ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
• [66] Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
• [67] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [68] All-trans retinoic acid inhibits the cell proliferation but enhances the cell invasion through up-regulation of c-met in pancreatic cancer cells. Cancer Lett. 2005 Jun 28;224(2):303-10. doi: 10.1016/j.canlet.2004.10.016. Epub 2004 Dec 8.
• [69] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [70] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [71] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [72] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [73] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [74] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [75] Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
• [76] D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
• [77] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [78] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [79] Identification of human cell responses to benzene and benzene metabolites. Genomics. 2007 Sep;90(3):324-33.
• [80] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [81] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [82] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [83] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [84] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [85] Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicol Lett. 2021 Mar 1;338:1-9. doi: 10.1016/j.toxlet.2020.11.011. Epub 2020 Nov 25.
• [86] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [87] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [88] Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
• [89] Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
• [90] Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFB and AhR and EGFR-ERK pathway. Toxicol Appl Pharmacol. 2011 Sep 1;255(2):138-49.
• [91] Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Mol Cell Neurosci. 2007 Mar;34(3):310-23. doi: 10.1016/j.mcn.2006.11.008. Epub 2006 Dec 28.
• [92] 2,3,7,8-tetrachlorodibenzo-p-dioxin augments the modulation of gene expression mediated by the thyroid hormone receptor. Toxicol Appl Pharmacol. 2004 Feb 1;194(3):201-10. doi: 10.1016/j.taap.2003.09.010.
• [93] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [94] Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
• [95] Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
• [96] Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
• [97] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [98] Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
• [99] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [100] Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
• [101] A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
• [102] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [103] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [104] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [105] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [106] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [107] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [108] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.